Výsledky vyhledávání

Earlier News: 2019 - 2018 We help inventions grow! BACK TO LATEST NEWS i&i Prague is joining Hello Tomorrow Ecosystem, a global community boosting deep technology-based start-ups Read More Novel partnership for iBodies has been facilitated by i&i Prague and IOCB Tech managers Read More Revolutionary type of catheter raised €2 million from private investors Read More A novel early cancer diagnostics method has been developed at University of Pardubice, partnered with i&i Prague Read More DIANA Biotechnologies, a novel startup in the i&i Prague´s academic incubator Read More i&i Prague became a shareholder in the spin-off XENO Cell Innovations! Read More i&i Prague co-invested Dracen Pharmaceuticals, a company developing a novel oncology treatment Read More i&i Prague successfully mediated an out-licensing of antibodies from IMG Read More Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world Read More

Earlier News: 2020 We help inventions grow! BACK TO LATEST NEWS Nanofibers from Technical University of Liberec brings new hope in fight against Covid-19 Read More Enantis – first biotechnology spin-off from Masaryk University in Brno Read More DIANA Biotechnologies – technology that raised EUR 3M in 3 years Read More License for use of iBodies® bought by Immunotech, a member of the Beckman Coulter group! Read More LAM-X: revolutionary wound-treating nanomaterials Read More Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer Read More LAM-X – light-activated nanomaterials for face-masks and respirators Read More Elphogene: non-invasive screening of patients in advanced stages of cancer Read More DRACEN Pharmaceuticals – Novel glutamine antagonist as anticancer therapies Read More iBodies – synthetic antibodies from Institute of Organic Chemistry and Biochemistry of the CAS Read More Elphogene in World Journal of Gastroenterology! Read More Prague startup RIOCATH had recently entered market with its world-unique catheter! Read More Czech anti-covid19 #hackathon won by two i&i Prague accelerated projects Read More LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19 Read More iBodies established cooperation with Ximbio, a TTO within the UK’s largest charity, Cancer Research UK Read More LAM-X: the spin-off accelerated by i&i Prague in Media Read More

About us We focus on the transfer of new technologies into practice. We are dedicated to innovations in the field of Drug Discovery, Diagnostics, MedTech and other Life Science fields originating from academic institutions. Our team supports the creation of spin-off companies and the sale of licenses. Meet our team Our Mission We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. Our Objective Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region. Our Team Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them. Our background We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people. Meet our team Meet Our Team Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them. Jiří Moos CEO, Board of Directors Jiří Moos is the Executive Director of our bio-innovation center i&i Prague. Read More David Stíbal Vice Director David Stíbal is the Vice Director at i&i Prague. Read More Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. Read More Simona Šandová Office Manager Simona Šandová is the Office Manager of i&i Prague. Read More Milan Prášil Chairman, Board of directors Milan Prášil is the Chairman of the Board of Directors. Read More Jaromír Zahrádka Business development Jaromír Zahrádka is responsible for business development Read More Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. Read More Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. Read More Alexandr Krajhanzl Board of Directors Alexandr Krajhanzl has joined i&i Prague since September 2021. Read More Iva Machová Project Manager Iva Machová is a Project Manager at i&i Prague. Read More Martin Kovalčík Communications Martin Kovalčík is our Communications Manager. Read More

i&i Prague Bio-Innovation Center We are the first choice partner and the leading institution for the best early-phase biotech innovations and smart money investments. We focus on projects from Central Europe. Read more We are i&i Prague , a bio-innovation center located right in the heart of Europe. Our objective is to identify the potential of new inventions in Drug Discovery, Diagnostics, MedTech and other Life Science fields . We do this by scouting for innovative projects and investing in the most promising ones. Then we will help with product development and, ultimately, market entry. ​ We can help you with Investment With our investment, we try to help innovative ideas in their transition from research projects to functional companies. Read more Partnering We are creating a unique network of partners that brings a long-term exchange of innovative ideas and original experiences. Read more Incubation We are your new team member, leading your journey from groundbreaking invention to market-storming product. Read more Education We offer exciting educational activities that introduce important topics connecting the worlds of science and business. Read more Excellence & Knowledge We are the center of excellence and a knowledge base. Commercalization Partner We facilitate discussions between spin-offs and industry. Complex Support We are the center of complex support for the best of all projects. Our role Our portfolio We focus on unique ideas that have the potential to succeed on a global scale. We are dedicated to innovations in Drug Discovery, Diagnostics, MedTech and other Life Science fields that originate from academic institutions. Read more i&i Biotech Fund I In 2021, we established the i&i Biotech Fund in cooperation with the European Investment Fund. It is the venture capital firm that invests in innovative European Life Sciences companies focused on Drug Discovery, Diagnostics, MedTech and other Life Science fields. Read more Mar 11 2024 This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as Christian A. Stein, Petr Jansa, and other leading experts. The capital city of the Czech Republic is set to host the second Prague.bio Conference on September 24th 2024. The event unites top minds in biotechnology, representatives from major investment funds, technology transfer law specialists and other professionals from the biotech and medtech sectors. For ticket purchases, the project registration form and the latest news visit: www.conference.prague.bio . Read more Jan 30, 2024 CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours CasInvent Pharma, a university spin-off focused on developing anti-cancer compounds, has successfully closed the Pre-Series A funding round, raising a total of € 1.6 million from both existing and new investors. Founded in 2020 as a spin-off from Masaryk University in Brno and with the support of i&i Prague, CasInvent Pharma specializes in the development of highly selective inhibitors targeting the casein kinase 1 enzyme family.... Read more Nov 30, 2023 IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023 Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio)... Read more Feb 7, 2023 New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. ... Read more Highlights Read more i&i Prague in numbers 15 We have created or otherwise supported 15 spin-off companies from 5 countries . 9 We have an equity stake in 9 spin-offs . We have already announced 3 exits. 1.8 Overall, the spin-offs in our portfolio have raised more than CZK 1.8 billion from other investors. 15 We helped sell 15 licenses to universities and other academic institutions. Our partners To play, press and hold the enter key. To stop, release the enter key. Read more

About us We focus on the transfer of new technologies into practice. We are dedicated to innovations in the field of Drug Discovery, Diagnostics, MedTech and other Life Science fields originating from academic institutions. Our team supports the creation of spin-off companies and the sale of licenses. Meet our team Our Mission We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. Our Objective Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region. Our Team Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them. Our background We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people. Meet our team Meet Our Team Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them. Jiří Moos CEO, Board of Directors Jiří Moos is the Executive Director of our bio-innovation center i&i Prague. Read More David Stíbal Vice Director David Stíbal is the Vice Director at i&i Prague. Read More Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. Read More Simona Šandová Office Manager Simona Šandová is the Office Manager of i&i Prague. Read More Milan Prášil Chairman, Board of directors Milan Prášil is the Chairman of the Board of Directors. Read More Jaromír Zahrádka Business development Jaromír Zahrádka is responsible for business development Read More Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. Read More Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. Read More Alexandr Krajhanzl Board of Directors Alexandr Krajhanzl has joined i&i Prague since September 2021. Read More Iva Machová Project Manager Iva Machová is a Project Manager at i&i Prague. Read More Martin Kovalčík Communications Martin Kovalčík is our Communications Manager. Read More

< Back i&i Prague became a shareholder in the spin-off XENO Cell Innovations! XENO Cell Innovations is a young, progressing company based in Pilsen, Czech Republic. It is focused mostly on bio-computing – capturing complex biological system in images, combining creative microscopy with a little narration and a lot of imagination to make more visible the amazing potential of computing in liquid media. Their technology is able to link up to biological objects generating a coherent intelligible interface. It self-assembles into computational clusters and processes information locally within these clusters. Rather than relying on brute-force screening, the linked biological sample reports on itself. Categorically, a cluster is a physically connected network made up of genetically engineered yeast, linkers, enzymes, and other chemical modifiers. Clusters are not prefabricated. They self-assemble around objects with specific immunological profiles. By fusing different fluorescent labels to different yeast strains, the makeup of a cluster can in part be made visible. ​ We, the i&i Prague, had this great opportunity to offer our services to this project and helped its creators reach their goal. Now, with the company established, we became a proud shareholder! ​ The motto of XENO Cell Innovations is: „Many foundational problems in diagnostics and bioengineering are solvable if biology could just do more of the work. But current biotech isn’t smart enough. We are interested in changing the status quo by systematizing biologic units and constructing modular composition rules“ . ​ To find out more about this growing company, SEARCH: https://xenocells.com/ Previous Next

< Back Martin Kovalčík Communications For almost 13 years, Martin worked as a media coordinator for the respected Czech non-profit organization, People in Need, where he was responsible for the media service for a team of 300 people. Also, he has experience working in several editorial offices. He left his most significant mark at the Metro newspaper, where he worked for over 5 years, the last two as the deputy editor-in-chief.

< Back LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19 During COVID-19 crisis we embrace our startups to answer current questions and solve present problems. Our the most recently established startup – LAM-X, a.s. – is not an exception. LAM-X a.s., a technological spin-off of the Charles University and the Czech Academy of Sciences, joined forces with the Technical University of Liberec (TUL) in the fight against COVID-19. Their common goal is to develop active nanofilters that not only capture but also actively remove viral particles. The nanofilters will be useful as part of face masks and respirators. In response to the current situation, the LAM-X adapted its R&D strategy and began developing self-sterilizing filters usable as “active layers” of face masks and respirators. To increase production capacity, LAM-X, an academic spin-off, started cooperation with the Institute for Nanomaterials, Advanced Technologies and Innovation of the Technical University of Liberec. This institute is known for its excellent expertise in the production of nanomaterials. ​ “Cooperation with the academic environment is and will undoubtedly be very important for our company. After all, the LAM-X proprietary technology is based on many years of research by the academic group of Associate Professor Jiří Mosinger from the Faculty of Science of the Charles University,” said Dr. Chaloupka, the CEO of the company.“We believe that by starting cooperation with the Technical University of Liberec, the technology will be prepared faster for the industrial production”, mentioned Dr. Barbora Šumová, the board member representing company’s financial investor i&i Prague s.r.o She added: “Currently, there are almost no nanotechnologies that would offer active elimination of viral particles and those existing differ greatly in their effectiveness. To ensure high quality and smooth certification process, we therefore want to first thoroughly test our material in cooperation with the academic and private sectors.” ​ The use of LAM-X nanofilters offers additional added value. The amount of healthcare waste produced during this crisis will represent a significant economic and environmental burden on society. LAM-X self-sterilizing nanomaterials, that are intended for reuse, could at least partially alleviate this undesirable situation. ​ To learn more about this interesting project, contact barbora.sumova@lam-x.tech . Previous Next

The judges at Transfera Technology Day 2021 awarded the cream of the crop This year at the 2nd Transfera Technology Day, the first place went to the Tablets for the Treatment of Contaminated Water. The second place was taken by the Microemulsions and Gels for Cleaning Surfaces of Historical Materials and the bronze went to the project aimed at detecting bacteria in amniotic fluid. The jury consisting of representatives of the business community, investors and organisers assessed the commercial potential of research projects of Czech universities and other research institutions. This year, they also awarded the Sympathy Prize for the first time – it went to the special oxygenation liners for fishing beads. The event aims at connecting science and business in order to get valuable feedback regarding the commercial potential of projects and secure future funding for promising research projects. ​ “Czech science and research has many talented people to offer. However, they need to be supported and motivated. That’s why we’re glad we can keep connecting the world of business with the great ideas of our scientists. Especially at its start, no project can survive without support,” says Eva Janouškovcová, chairwoman of the Transfera.cz association, the co-organizer of the event. ​ Battle of Universities, Research Institutes and Hospitals 13 scientific research projects were selected as finalists (aside from the first three projects, there were e.g. the Electrostatic Separation of Plastics to Improve Wate Separation, the Pad for Sensing the Load and Position of the Patient or the Device for Coating Wires in Implant Surgery). There were teams of scientists from the Czech Technical University in Prague, the National Institute of Mental Health, J. Heyrovský Institute of Physical Chemistry, the University of West Bohemia, Palacký University Olomouc, The University of Hradec Králové, Brno University of Technology, University Hospital Hradec Králové, VSB – Technical University of Ostrava, Masaryk University, the Institute of Rock Structure and Mechanics CAS, the Institute of Geonics CAS and the University of South Bohemia in České Budějovice. The jury chose the best three out of these teams. ​ The winning project of the Palacký University Olomouc is meant to be used mainly in case of natural disasters or industrial accidents. The new effervescent tablets for the treatment of contaminated water are easy to store and use – you simply put them in the contaminated water. Thanks to being “fizzy”, they take effect very quickly. The tablet dissolves completely in just 30 seconds allowing the active ingredient to perform its function. Moreover, they do not contain any toxic substances and are environmentally friendly. ​ The second place went to the Microemulsions and Gels for Cleaning Surfaces of Historical Materials developed by the team of J. Heyrovský Institute of Physical Chemistry CAS. These extremely gentle yet effective microemulsion cleaning systems are designed to remove unwanted substances from various valuable historical artefacts. The main component here is water – the content of the active ingredients is very low, yet they are highly effective. ​ The third place went to the University Hospital Hradec Králové and their project Detection of Bacteria in Amniotic Fluid in Patients with Preterm Prelabour Rupture of Membranes. This new method helps detect the presence of specific bacteria in amniotic water in just a couple of hours. Thanks to this, it will be possible to initiate effective antibiotic treatment in time and reduce the adverse effects on the fetus. ​ Sympathy Prize Will Help Fish The Sympathy prize was won by the Aeration and Oxygenation Liner in Fishing Beads from the University of South Bohemia in České Budějovic. This liner should improve the conditions of the fish stored in beads e.g. when fishing out ponds or during pre-Christmas sales. The new liner will provide sufficient oxygenation of water without the necessity of weighting down the aeration hoses, which complicates catching the fish and often results in injuring them. ​ Winners Got Both Money and Well-deserved Attention The projects that made it to the finals can use the title Finalist of TRANSFERA TECHNOLOGY DAY 2021. The winning project was awarded the title Winner of TRANSFERA TECHNOLOGY DAY 2021. The certificate is a mark of quality and can help secure not only financial support. The finalists will also receive an invitation to the Technological Incubation project of the CzechInvest agency who can allocate funding of up to CZK 5 million to each project. ​ The jury that evaluated both the presentations and the commercial potential of the projects consisted of the representatives of investors and other experts – Petra Gordan (Nation1), Jaromír Zahrádka and Barbora Šumová (i&i Biotech Fund), Jakub Domitra (Busyman), Eva Janouškovcová and Petr Kubečka (Transfera.cz), Jiří Krechl (CzechInvest), Robert Reich (Lighthouse Ventures) and Václav Novák and Jaroslav Řasa (NEURON Endowment Fund). ​ The competition has been organized by Transfera.cz together with its general partner CzechInvest and other partners (e.g. Technology Agency of the Czech Republic, NEURON Endowment Fund, vedavyzkum.cz and others). ​ A record of the event can be found at www.transfera.cz .

< Back Elphogene: non-invasive screening of patients in advanced stages of cancer Elphogene s.r.o. is a Czech spin-off company that succeeds decades of intensive research performed at Genomac research centre as well as thanks to collaborations with leading oncology centres. Using their technology oncoMonitor™ – a diagnostic tool based on so-called liquid biopsy – Elphogene brings a non-invasive screening of patients in advanced stages colorectal cancer. Biggest advantages of oncoMonitor™ technology are its speed and accuracy in diagnosing possible relaps of the tumor growth after a successful surgery. Elphogene s.r.o. has received an initial investment from i&i Prague in order to implement its oncoMonitor™ for a diagnostic monitoring screening of ctDNA in peripheral blood of patients in advanced stages of cancer. The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute , a leading Czech private research center widely recognized for its strong record of scientific projects in clinical cancer genomics. ​ The purpose of the oncoMonitor™ test is a follow-up of patients in advanced stages of cancer for early detection of newly arising metastatic lesions. The technology is capable of capturing ctDNA in up to 88% of patients with advanced colorectal cancer with the presence of liver metastases which is more accurate and lacking the negative impact on health (such as radioactive doses) than current approaches (ultrasonography, magnetic resonance, and especially X-ray examination and computed tomography – CT). ​ ​ To learn more about this technology: elphogene.cz . Previous Next

< Back i&i Prague is joining Hello Tomorrow Ecosystem, a global community boosting deep technology-based start-ups In mid-June 2018 a new partnership has been established between a Prague-based company focused on central and east European biotech start-ups in the early stage of development and a global organisation which gives a platform for deep technology-based start-ups all over the world, Hello Tomorrow. i&i Prague has joined the Ecosystem Partners of Hello Tomorrow , which aims to connect current and future start-ups coming from the i&i Prague´s incubator to the global start-up scene and increase their visibility, e.g. by participating in the Global Challenge and other activities organized by Hello Tomorrow. Additionally, the collaboration will help Hello Tomorrow and its partners to connect and tap into unsuspected opportunities and projects in biotech and deep technologies originating in central and east Europe. ​ About Hello Tomorrow Hello Tomorrow is a non-profit organisation bringing together a community of actors aiming to unlock the potential of deep technologies to solve the world’s toughest challenges. They source deeptech projects and startups and facilitate collaboration between entrepreneurs, industries and investors in order to propel innovation from the lab to the market. Hello Tomorrow organises startup competitions, mentorship programs and a series of events around the world, as well as educating and consulting relevant stakeholders on emergence of deep technologies. Hello Tomorrow is fast becoming a key reference platform in deeptech innovation and entrepreneurship. Previous Next

i&i Prague announces its first exit, DIANA Biotechnologies is bought out by its founders Prague, 21 February 2022 – BTND a.s. has completed the buyout of DIANA Biotechnologies from the portfolio of biotech incubator i&i Prague. For i&i Prague, the transaction opens up new opportunities to support other scientific projects. i&i Prague acquired a stake in DIANA Biotechnologies at its inception, reflecting the important role of the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB) in the early development of DIANA technology prior to the company’s establishment. However, DIANA Biotechnologies has gradually become a successful biotechnology company that is independently developing a number of other new technologies. It has also made a positive contribution to the fight against the COVID-19 epidemic by developing unique PCR assays, significantly increasing the Czech testing capacity. DIANA Biotechnologies is now facing major investments in further development and it made sense for i&i Prague to make its first exit. BTND a. s., a company backed by DIANA Biotechnologies co-founders Václav Navrátil and Martin Dienstbier, together with the Czech investment group BTCZ, is buying the stake from i&i Prague. „In less than four years DIANA Biotechnologies has moved from a spin-off project to a broad-based and independent company. We are now facing heavy investment in building a state-of-the-art scientific facility and in developing projects in drug development and monoclonal antibody development. Our goal is to build an innovative biopharmaceutical company that will work closely with Czech academia. I am pleased that our success will also help other promising scientific projects,“ said Václav Navrátil, co-founder and director of DIANA Biotechnologies. ​ The transaction is also considered a great success by the incubator i&i Prague, where it is the first purchase of a share of the company from their portfolio. “We were honored to be at the birth of this project. It is the first swallow, which completes several years of efforts of our entire team and which also confirms the sense and correctness of our steps and vision. We will use the funds raised through this transaction to support other interesting startups and spin-off companies from the academic sphere in the Czech Republic and Europe,“ explained Jaromír Zahrádka, founder and director of i&i Prague. About i&i Prague The i&i Prague biotech incubator was founded in 2017 and has become part of a unique ecosystem that has formed around the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB). Since its establishment, this incubator has been dedicated to investing in academia and supporting the transition of scientific discoveries into practice. Currently, i&i Prague has in its portfolio the shares of 10 spin-off companies, promising projects from all over Europe or the USA, in which it has invested a total of approximately EUR 3 million. In addition, it has helped these early stage companies to raise another approximately EUR 75 million from investors not only from Europe but from all over the world. About DIANA Biotechnologies The i&i Prague biotech incubator was founded in 2017 and has become part of a unique ecosystem that has formed around the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB). Since its establishment, this incubator has been dedicated to investing in academia and supporting the transition of scientific discoveries into practice. Currently, i&i Prague has in its portfolio the shares of 10 spin-off companies, promising projects from all over Europe or the USA, in which it has invested a total of approximately EUR 3 million. In addition, it has helped these early stage companies to raise another approximately EUR 75 million from investors not only from Europe but from all over the world.